Grant ID RP200392
Awarded On August 19, 2020
Title Harnessing Aurora Kinase Inhibition-Induced Cell Death to Enhance Immunotherapy in HPV- Driven Cancers
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Clinical Translation
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Jagannadha Sastry
Cancer Sites Cervix Uteri, Head and Neck, Penis
Contracted Amount $1,199,997*

*Pending contract negotiation

Lay Summary

Human papillomavirus (HPV)-driven cancers are common and lethal. There are no effective targeted therapies for HPV+ cancers. Most of those who progress after initial therapy with radiation and chemotherapy die within 3 years, demonstrating unmet clinical need. Immunotherapy (ICT) is effective for recurrent HPV+ cancers, but with response rates of and a one-year survival rate of 40%. To address the unmet need for biomarker-driven therapy for HPV+ cancers, we tested the efficacy of 721 drugs in HPV+ and negative cell lines and identified Aurora kinase inhibitors as the only class of drugs that was more effective in HPV+ cell lines. We demonstrated that Aurora kinase inhibition leads to HPV+ ca...

Read More